

DAFTAR PUSTAKA

- Adibkia, K., Javadzadeh, Y., Dastmalchi, S., Mohammadi, G., Niri, F. K., & Alaei-Beirami, M., 2011, Naproxen-Eudragit RS 100 nanoparticles: Preparation and physicochemical characterization, *Colloids and Surfaces. B, Biointerfaces*, 83(1), <https://doi.org/10.1016/j.colsurfb.2010.11.014>
- Akhgari, A., & Tavakol, A., 2016, Prediction of Optimum Combination of Eudragit RS/Eudragit RL/Ethyl Cellulose Polymeric Free Films Based on Experimental Design for Using as a Coating System for Sustained Release Theophylline Pellets. *Advanced pharmaceutical bulletin*, 6(2), 219–225. <https://doi.org/10.15171/apb.2016.030>
- Alam, S., Aslam, M., Khan, A., Imam, S.S., Aqil, M., Sultana, Y., & Ali, A., 2016, Nanostructured lipid carriers of pioglitazone for transdermal application: From experimental design to bioactivity detail. *Drug Delivery*, 23(2), 601–609. <https://doi.org/10.3109/10717544.2014.923958>
- Argade, P.S., Magar, D.D., Saudagar B., 2013, Solid Dispersion: Solubility Enhancement Technique for poorly water soluble Drugs; *J. Adv. Pharm. Edu. & Res.* 2013: 3(4): 427-439.
- AOAC, 2019, Apendix F: Guidelines for Standar Method Performance Requierements, *AOAC Official Methods of Analysis*. AOAC International, pp. 1–18.
- Bhosale, U.M., Galgatte, U.C., & Chaudhari, P.D., 2016, Development of pioglitazone hydrochloride lipospheres by melt dispersion technique: Optimization and evaluation, *Journal of Applied Pharmaceutical Science*, 6,(1), 107–117. <https://doi.org/10.7324/JAPS.2016.600118>
- Boddupalli, B.M., Masana, P., Anisetti, R.N., Kallem, S.V., & Madipoju, B., 2013, Formulation and evaluation of Pioglitazone loaded Bovine serum albumin nanoparticles along with Piperine, *Drug Invention Today*, 5(3), 212–215. <https://doi.org/10.1016/j.dit.2013.05.011>
- Cahyani, S., Sulastari, & Laksitorini, M., 2024, Perbandingan Disolusi Dispersi Padat Valsartan Dalam Bentuk Tablet dan Kapsul, *Majalah Farmaseutik*, 20(2), 194. <https://doi.org/10.22146/farmaseutik.v20i2.94205>
- Choi, J.S., dan Park, J.S., 2017, Design of PVP/VA S-630 based tadalafil solid dispersion to enhance the dissolution rate, *European Journal of Pharmaceutical Sciences*, 97, pp. 269–276. <https://doi.org/10.1016/j.ejps.2016.11.030>
- Craye, G., Löbmann, K., Grohganz, H., Rades, T., & Laitinen, R., 2015, Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying, *Molecules*, 20(12), 21532–21548. <https://doi.org/10.3390/molecules201219784>
- Dave, V., Telange, D., Denge, R., Patil, A., Umekar, M., & Gupta, S.V., 2018, Pentaerythritol as an excipient/solid-dispersion carrier for improved solubility and permeability of ursodeoxycholic acid, *Journal of Excipients and Food Chemicals*, 9, 80–95.
- DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S. T., Nolin, T.D., & EllingRod, V., 2020, *Pharmacotherapy: A Pathophysiologic Approach* (11th ed.). McGraw

- Hill, Dillen, K., Vandervoort, J., Mooter, G., Ludwig, A., 2006, Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles, *International Journal of Pharmaceutics*, 314 (1), 72-82, <https://doi.org/10.1016/j.ijpharm.2006.01.041>
- Dhuri, A., Sarma, D., Nair, R., Paul, P., Sharma, B., Munagalasetty, S., Bhandari, V., Singh, P., 2024, Fabrication of Amorphous solid Dispersion of Entacapone for Enhanced Solubility and Dissolution Rate: Morphology, Solid State Characterization, In silico Molecular Docking Studies, *Journal of Molecular Structure*. 1324. 140851. 10.1016/j.molstruc.2024.140851.
- Dos Santos J., Da Silva G.S., Velho M.C., Beck R., 2021, Eudragit®: A Versatile Family of Polymers for Hot Melt Extrusion and 3D Printing Processes in Pharmaceutics. *Pharmaceutics*. 13(9):1424. doi: 10.3390/pharmaceutics13091424.
- Elbary, A.A., Kassem, M.A., Abou Samra, M.M., & Khalil, R.M., 2008, Formulation and hypoglycemic activity of pioglitazone-cyclodextrin inclusion complexes. *Drug Discoveries & Therapeutics*, 2(2), 94–107.
- Gupta, R.A., & Kumar, P.O., 2021, Development and Characterization of Pioglitazone Nanoparticles for the Effective Treatment of Diabetes Mellitus. *Journal of Pharmaceutical Research International*, 33(31A), 172–182. <https://doi.org/10.9734/jpri/2021/v33i31A31678>
- Goudon, F., Clement, Y., Ripoll, L., 2020, Controlled Release of Retinol in Cationic Co-Polymeric Nanoparticles for Topical Application. *Cosmetics*. 7. 29. 10.3390/cosmetics7020029
- Hayyat, A., & Siddique, N., 2023, Individual and Combined Effect of Eudragit® RS 100 and Eudragit® RL 100 on Sustained Release Characteristics of Ropinirole HCl-loaded Microparticles, *Pharmaceutical Sciences and Research: Vol. 10: No.2, Article 6*. DOI: 10.7454/psr.v10i2.1265
- He, W., Li, Y., Zhang, R., Wu, Z., & Yin, L., 2014, Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: Preparation and in vitro/in vivo evaluation. *International Journal of Pharmaceutics*, 476(1–2), 223–231. <https://doi.org/10.1016/j.ijpharm.2014.09.056>
- Hyma, P., & Abbulu, K., 2013, Formulation and characterisation of self microemulsifying drug delivery system of pioglitazone. *Biomedicine & Preventive Nutrition*, 3(4), 345–350. <https://doi.org/10.1016/j.bionut.2013.09.005>
- IDF, 2023, Type 2 diabetes. International Diabetes Federation. <https://idf.org/aboutdiabetes/type-2-diabetes/>
- ICH, 2005, Q2 (R1), "Validation of analytical procedures: Text and methodology" ICH Harmonised Tripartite Guideline. *International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals* <https://doi.org/10.1163/ej.9789004163300.i-1081.897>
- Ilevbare, G.A., Liu, H., Edgar, K.J., & Taylor, L.S., 2013, Impact of polymers on crystal growth rate of structurally diverse compounds from aqueous solution. *Molecular Pharmaceutics*, 10(6), 2381–2393. <https://doi.org/10.1021/mp400029v>

- Jafari, E., 2013, Preparation, characterization and dissolution of solid dispersion of diclofenac sodium using eudragit E-100, *Journal of Applied Pharmaceutical Science*, 3(8), JAPS.2013.3829
- Jagtap, K., Patel, S., Shah., 2023, Dissolution Method development and validation for simultaneous determination of Metformin and Teneligliptin in pharmaceutical tablets. *Research Journal of Pharmacy and Technology*; 16(1):133-9. doi: 10.52711/0974-360X.2023.00025
- Roden M., Shulman G.I., 2019, The integrative biology of type 2 diabetes. *Nature*. ;576:51–60. <https://doi.org/10.1038/s41586-019-1797-8>.
- Sapkal, S. B., Adhao, V. S., Thenge, R. R., Darakhe, R. A., Shinde, S. A., & Shrikhande, V. N., 2020, Formulation and Characterization of Solid Dispersions of Etoricoxib Using Natural Polymers, *Turkish Journal of Pharmaceutical Sciences*, 17(1), 7-19. <https://doi.org/10.4274/tjps.galenos.2018.04880>
- Shaveta, S., Singh, J., Afzal, M., Kaur, R., Imam, S.S., Alruwaili, N.K., Alharbi, K.S., Alotaibi, N.H., Alshammari, M.S., Kazmi, I., Yasir, M., Goyel, A., & Ameenuzzafar., 2020, Development of solid lipid nanoparticle as carrier of pioglitazone for amplification of oral efficacy: Formulation design optimization, in-vitro characterization and in-vivo biological evaluation, *Journal of Drug Delivery Science and Technology*, 57, 101674. <https://doi.org/10.1016/j.jddst.2020.101674>
- Swain, R. P., & Subudhi, B. B., 2019, Effect of semicrystalline copolymers in solid dispersions of pioglitazone hydrochloride: in vitro-in vivo correlation, *Drug Development and Industrial Pharmacy*, 45(5), 775–786. <https://doi.org/10.1080/03639045.2019.1572183>
- Swain, R.P., Elhassan, G.O., Bhattacharjee, A., Sahu, R.K., Khan. J., 2024, Improved Dissolution Time and Oral Bioavailability of Pioglitazone Using Lquisolid Tablets: Formulation, In Vitro Characterization, and In Vivo Pharmacokinetics in Rabbits, *ACS Omega*, 9 (42), 42687-42697 DOI: <https://doi.org/10.1021/acsomega.3c09145>
- Pandey, V., & Kohli, S., 2017, SMEDDS of pioglitazone: Formulation, in-vitro evaluation and stability studies. *Future Journal of Pharmaceutical Sciences*, 3(1), 53–59. <https://doi.org/10.1016/j.fjps.2017.02.003>
- Pandi, P., Bulusu, R., Kommineni, N., Khan, W., & Singh, M. (2020). Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. *International Journal of Pharmaceutics*, <https://doi.org/10.1016/j.ijpharm.2020.119560>
- Pavia, D. L., Lampman, G. M., Kriz, G. S., & Vyvyan, J. A., 2014, *Introduction to spectroscopy* (5th ed.), Cengage Learning.
- PERKENI, 2021, Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di INDONESIA - 2021.
- Prasad, P.S., Imam, S.S., Aqil, M., Sultana, Y., & Ali, A., 2016, QbD-based carbopol transgel formulation: Characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes. *Drug Delivery*, 23(3), 1047–1056. <https://doi.org/10.3109/10717544.2014.936536>

- PubChem, 2024a, *Pioglitazone*, <https://pubchem.ncbi.nlm.nih.gov/compound/4829>
- PubChem, 2024b, *Pentaerythritol*,
<https://pubchem.ncbi.nlm.nih.gov/compound/8285>
- PubChem, 2024c, *Eudragit RS*
<https://pubchem.ncbi.nlm.nih.gov/compound/104931>
- Tekade, A., & Yadav, J., 2020, A Review on Solid Dispersion and Carriers Used Therein for Solubility Enhancement of Poorly Water Soluble Drugs. *Advanced Pharmaceutical Bulletin*. 10. 359-369. 10.34172/apb.2020.044.
- Telange, D.R., Bhaktani, N.M., Hemke, A.T., Pethe, A.M., Agrawal, S.S., Rarokar, N.R., & Jain, S.P., 2023, Development and Characterization of Pentaerythritol-Eudragit RS100 Co-processed Excipients as Solid Dispersion Carriers for Enhanced Aqueous Solubility, In Vitro Dissolution, and Ex Vivo Permeation of Atorvastatin, *ACS Omega*, 8(28), 25195–25208.
<https://doi.org/10.1021/acsomega.3c02280>
- Trapani, A., Laquintana, V., Denora, N., Lopodota, A., Annalisa, C., Franco, M., Trapani, G., Liso, G., 2007, Eudragit RS 100 microparticles containing 2-hydroxypropyl- β -cyclodextrin and glutathione: Physicochemical characterization, drug release and transport studies. *European journal of pharmaceutical sciences*. 30. 64-74. 10.1016/j.ejps.2006.10.003.
- Vasconcelos, T., Sarmiento, B., & Costa, P., 2007, Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs, *Drug Discovery Today*, 12(23–24), <https://doi.org/10.1016/j.drudis.2007.09.005>
- Vo CL, Park C, Lee BJ., 2013, Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. *Eur J Pharm Biopharm*. 85(3 Pt B):799-813, <https://doi.org/10.1016/j.ejpb.2013.09.007>.
- WHO, 2023, *Diabetes*. World Health Organization.
<https://www.who.int/healthtopics/diabetes>
- Yan, Y., Wu, T., Zhang, M., Li, C., Liu, Q., & Li, F., 2022, Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population, *BMC Public Health*, 22(1), Article 1.
<https://doi.org/10.1186/s12889-022-13759-9>
- Zhang, J., Han, R., Chen, W., Zhang, W., Li, Y., Ji, Y., Ouyang, D., 2018, Analysis of the literature and patents on solid dispersions from 1980 to 2015, *Molecules*, 23(7), 1–19. <https://doi.org/10.3390/molecules23071697>